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Dear Sir,
In the December 2006 issue of Journal of Viral Hepatitis,
Drs. Gish and Gadano made the important point that the
current prevalence estimate of 1.25 million individuals in
the USA with chronic hepatitis B virus (HBV) infection
should be corrected by taking into account HBV prevalence
in immigrant populations and current estimates may be as
high as 2 million [1]. The Hepatitis B Foundation (HBF)
agrees with this statement, that the prevalence of chronic
HBV infection in the United States is, in fact, signiﬁcantly
greater than the currently accepted estimate. We have per-
formed our own calculation of the chronic hepatitis B
prevalence estimate including the high prevalence rates of
hepatitis B in immigrant populations. As a result, we esti-
mate the current burden of chronic hepatitis B in the USA to
be approximately 2 million people.
We reason that an underestimation of the true number of
infected individuals in the USA has occurred mostly because
the highest-risk populations are under-represented in sur-
veillance studies, and a large percentage of chronically
infected individuals remain undiagnosed. Estimates of the
number of HBV infections in the USA have been based on
serosurvey data from the National Health and Nutrition
Examination Surveys for the years 1976–1994 (NHANES II,
III), which did not include signiﬁcant numbers of Asians and
Paciﬁc Islanders (API, the ethnic groups most affected by
hepatitis B), making it difﬁcult to obtain accurate prevalence
estimates [2]. Also, the large inﬂux of foreign born individ-
uals from countries with moderate or high incidence
of hepatitis B increases the limitation of the NHANES
estimate.
Using Census data (2005 American Community Survey)
and current prevalence estimates for chronic hepatitis B,
we calculate that in APIs alone, there are approximately
832 433 individuals chronically infected with hepatitis B
(Table 1). This number was reached using hepatitis B
prevalence estimates of 8.9% for foreign and 1.4% for US
born APIs [3], based on HBV survey data of API pregnant
women. These estimates are conservative in comparison
with recent studies, which have found the prevalence among
foreign-born APIs to be between 10–15% [4,5].
We calculated a chronic HBV burden of 1 157 137
individuals in the Caucasian, African American, and
other ethnicities, with a prevalence estimate of 0.42% in
these groups (based on NHANES III data [6]) (Table 1).
Adding our estimate for the API population (832 433)
brings the total burden estimate to 1 989 570. This rep-
resents an increase of almost 800 000 individuals from
the currently accepted HBV prevalence estimate, and it
does not account for undocumented APIs, which could
increase the number of chronically infected by another
100 000 (there are an estimated 1 500 000 undocu-
mented APIs in the USA [7]). This calculation also does
not include other high-risk groups, such as the incarcer-
ated and homeless populations, which would increase the
burden even further.
While these calculations have limitations, they are pro-
vocative, in that they highlight the strong likelihood that
chronic hepatitis B remains an under-recognized disease in
the USA, one that deserves greater priority from public
health leaders, research institutions and clinicians. The na-
tion needs to support public health surveillance systems that
yield reliable state and local data and can be used to cal-
culate more accurate estimates of chronic hepatitis B.
As the readers of JVH are aware, chronic hepatitis B
infection leads to serious liver disease and early death in up
to 25% of individuals [8], and the direct and indirect
ﬁnancial burden of chronic hepatitis B reaches $1 billion
each year [9]. It is a leading cause of primary liver cancer
(hepatocellular carcinoma), which is rising in both incidence
and mortality in the USA, and now ranks 8th among leading
causes of cancer death for Americans [10]. In the API pop-
ulation, liver cancer ranks 3rd among causes of cancer
death [11].
With the number of new infections remaining steady
despite the availability of a vaccine, and the signiﬁcant rise of
primary liver cancer in the USA, it is imperative that
hepatitis B be prioritized as an important public health
concern. An accurate assessment of the true prevalence of
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high-risk, undercounted populations, is a crucial ﬁrst step
towards signiﬁcantly reducing the burden of chronic
hepatitis B in this country. The Hepatitis B Foundation calls
for action to be taken to allow all individuals in the USA who
are chronically infected with hepatitis B to be counted.
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Table 1 Estimate of hepatitis B preva-
lence in the USA, based on census data
and prevalence estimates, by ethnicity Ethnic group
Population size,
USA*
Prevalence of
chronic HBV

Total chronic
HBV infection
US born API 4 171 909 1.4% 58 406
Foreign-born API 8 696 936 8.9% 774 027
African–American 34 962 569 0.42% 146 842
Caucasian 215 333 394 0.42% 904 400
Other ethnicities 25 213 329 0.42% 105 895
Total: 1 989 570
*Population sizes based on the US Census Bureau, 2005 American Community
Survey [12].
Hepatitis B prevalence for APIs is based on data from the Asian Liver Center at
Stanford University [3]. Prevalence for all other ethnicities is based on NHANES III
data [6].
Letter to the Editor 13
 2007 The Authors
Journal compilation  2007 Blackwell Publishing Ltd